Table 1.
Application of advanced brain imaging in PCNSL diagnosis and monitoring.
| Diagnosis | Monitoring | |
|---|---|---|
| MRI DWI/ADC | (i) Marked reduction of ADC values in PCNSL in comparison to HGGs and TDLs | (i) No clear data |
|
| ||
| MRI spectroscopy | (i) Higher lip/Cr ratios in PCNSL in comparison to nonnecrotic areas of HGGs (ii) Similar MRS patterns between PCNSL and TDLs |
(i) Useful for metabolic information about T2-FLAIR hyperintense lesions |
|
| ||
| MRI perfusion | (i) Lower rCBV values in comparison to GBMs | (i) No clear data |
|
| ||
| 18 F-FDG-PET | (i) Homogeneous FDG uptake in PCNSL versus inhomogeneous uptake in GBMs or metastases | (i) Useful for assessment of treatment response (ii) Useful for metabolic information about T2-FLAIR hyperintense lesions (iii) Potential role for postchemotherapy FDG-PET in predicting PFS/OS |
|
| ||
| MET-PET | (i) Limited experience (ii) Potential role for the identification of disseminated or nonenhancing lesions |
(i) Useful for assessment of treatment response (ii) Potential role for tumor delineation after CT and RT; potential role for |
| detection of residual tumor | ||